|
|
|
|
| LEADER |
02637nmm a2200313 u 4500 |
| 001 |
EB001189958 |
| 003 |
EBX01000000000000000862095 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
160406 ||| eng |
| 020 |
|
|
|a 9783319278803
|
| 100 |
1 |
|
|a Cerci, Juliano
|e [editor]
|
| 245 |
0 |
0 |
|a Oncological PET/CT with Histological Confirmation
|h Elektronische Ressource
|c edited by Juliano Cerci, Stefano Fanti, Dominique Delbeke
|
| 250 |
|
|
|a 1st ed. 2016
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2016, 2016
|
| 300 |
|
|
|a VII, 97 p. 53 illus. in color
|b online resource
|
| 505 |
0 |
|
|a PART I. Biopsy guided PET/CT: Principle of biopsy guided imaging.- FDG PET/CT to guide biopsy: methods.- FDG PET/CT to guide biopsy: type of acess.- PART II. FDG PET/CT in lymphoma: Need of biopsy in lymphoma.- FDG PET/CT to guide biopsy in lymphoma: results.- PART III. FDG PET/CT in pancreatic lesions:Need of biopsy in pancreatic lesions.- FDG PET/CT to guide biopsy in pancreatic lesions: results.- PART IV. FDG PEM in breast lessions: Need of biopsy in breast lesions.- FDG PEM to guide biopsy in breast lesions: results -- PART V. PET/CT and CNS malignancies: Need of biopsy in CNS malignancies -- FDG PET/CT to guide biopsy in CNS: results -- PART VI. PET/CT and prostate cancer -- Choline PET/CT to guide biopsy in prostate cancer diagnosis -- PART VII. FLT PET/CT in cancer diagnosis: FLT PET/CT in cancer diagnosis: results
|
| 653 |
|
|
|a Nuclear Medicine
|
| 653 |
|
|
|a Nuclear medicine
|
| 653 |
|
|
|a Oncology
|
| 653 |
|
|
|a Pathology
|
| 700 |
1 |
|
|a Fanti, Stefano
|e [editor]
|
| 700 |
1 |
|
|a Delbeke, Dominique
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 028 |
5 |
0 |
|a 10.1007/978-3-319-27880-3
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-27880-3?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.0757
|
| 520 |
|
|
|a This book reviews the important new field of PET/CT-guided biopsy, which is of potential value in optimizing the diagnostic yield of biopsies. The role of this technology is examined in a range of malignancies, including lymphoma, pancreatic, breast cancer and CNS malignancies. True positive and false positive cases are presented and discussed, and many aspects of PET and pathology are addressed. The book describes many case presentations illustrated with mostly 18F-FDG PET/CT images, but also other PET radiopharmaceuticals such as 18F-FLT. The three editors are expert nuclear medicine physicians from Europe and North and South America, and the range of experiences gained in using PET/CT across the globe is reflected in the book
|